5Perez-Soler R,Chachoua A,Hammond LA,et al.Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer[J].J Clin Oncol,2004,22(16):3 228.
6Herbst RS,Johnson DH,Mininberg E,et al.Phase Ⅰ/Ⅱtrial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with non-small-cell lung cancer[J].J Clin Oncol,2005,23(11):2 544.
7Herbst RS,Prager D,Hermann R,et al.TRIBUTE:A phase Ⅲ trial of erlotinib hydroehloride(OSI-7474)combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer[J].J Clin Oncol,2005,23(25):5 892.
4Oh MJ, Choi JH, Kim IH, et al. Detection of epidermal growth receptor factor in the serum of patients with cervical carcinoma [ J ]. Clin Cancer Res,2000 ,6 :4760 - 4763.
5Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatmeat of cancer[ J]. J Clin Oncol,2003,21 (14) :2787 - 2799.
6Pinaki R Dutta,Amit Maity. Cellular responses to EGFR inhibitors and their relevance to cancer therapy [ J ]. Cancer Lett, 2007,254 (2) :165 - 177.
7Cong Cao, Shan Lu, Alex Sowa, et al. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs [ J ]. Cancer Lett, 2008,266 ( 2 ) : 249 - 262.
8Sebastian S, Settleman J, Reshkins J, et al. The complexity of targeting EGFR signalling in cancer : from expression to turnover [ J ]. Biochim Biophys Acta,2006,1766 ( 1 ) : 120 - 139.
9Peter O Hackel, Esther Zwick, Norbert Prenzel, et al. Epidermal growth factor receptors: critical mediators of multiple receptor pathways[J]. Current Opinion in Cell Biology,2008,11 (2) : 184 - 189.
10Dziadziuszko R, Witta SE, Cappuzzo F, et al. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non - small cell lung cancer[J]. Clin Cancer Res, 2006,12:3078 - 3084.
